TRVI Logo

Trevi Therapeutics, Inc. (TRVI) 

NASDAQ
Market Cap
$209.84M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
739 of 774
Rank in Industry
409 of 432

Largest Insider Buys in Sector

TRVI Stock Price History Chart

TRVI Stock Performance

About Trevi Therapeutics, Inc.

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in …

Insider Activity of Trevi Therapeutics, Inc.

Over the last 12 months, insiders at Trevi Therapeutics, Inc. have bought $0 and sold $570,473 worth of Trevi Therapeutics, Inc. stock.

On average, over the past 5 years, insiders at Trevi Therapeutics, Inc. have bought $22.8M and sold $251,021 worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 2,631,578 shares for transaction amount of $5M was made by NEA 16 GP, LLC () on 2022‑04‑11.

List of Insider Buy and Sell Transactions, Trevi Therapeutics, Inc.

2024-09-09SalePresident & CEO
1,840
0.0025%
$3.04$5,5870.00%
2024-09-06SalePresident & CEO
4,219
0.006%
$3.03$12,784+5.76%
2024-09-05SalePresident & CEO
40,277
0.0557%
$3.11$125,310+0.65%
2024-09-04SalePresident & CEO
10,981
0.0155%
$3.02$33,205+5.59%
2024-09-03SalePresident & CEO
3,863
0.0054%
$3.02$11,677+4.71%
2024-08-27Saledirector
4,555
0.0063%
$2.93$13,353+6.53%
2024-08-19SaleChief Scientific Officer
16,496
0.0227%
$2.96$48,883+3.37%
2024-08-16SaleChief Scientific Officer
18,660
0.0268%
$2.76$51,440+7.74%
2024-08-15SaleChief Scientific Officer
12,745
0.0185%
$2.79$35,5130.00%
2024-08-14SaleChief Scientific Officer
100
0.0001%
$2.75$2750.00%
2024-05-29SaleChief Scientific Officer
53,368
0.0761%
$2.55$136,110+16.60%
2024-05-22SaleChief Financial Officer
4,350
0.0062%
$2.64$11,485+12.17%
2024-05-20SalePresident & CEO
25,037
0.0359%
$2.86$71,576+2.83%
2024-05-10SalePresident & CEO
4,578
0.0069%
$2.90$13,276+6.59%
2023-10-11SaleChief Financial Officer
785
0.0012%
$2.02$1,586+29.90%
2023-09-11SaleChief Financial Officer
711
0.0011%
$2.20$1,564+12.39%
2023-08-11SaleChief Financial Officer
682
0.0011%
$2.36$1,610-5.04%
2023-07-11SaleChief Financial Officer
687
0.0007%
$2.34$1,608-1.32%
2023-06-12SaleChief Financial Officer
610
0.0006%
$2.64$1,610-11.72%
2023-05-11SaleChief Financial Officer
562
0.0008%
$2.89$1,624-25.50%

Insider Historical Profitability

<0.0001%
Meeker David Pdirector
352489
0.4586%
$2.7311<0.0001%
GOOD JENNIFER LPresident & CEO
213313
0.2775%
$2.7317<0.0001%
BASKETT FOREST
10421428
13.558%
$2.7331+1.73%
Makhzoumi Mohamad
10421428
13.558%
$2.7331+1.73%
NEA 16 GP, LLC
10421428
13.558%
$2.7310<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Nea Management Company Llc$39.23M16.1411.37M0%+$00.18
Frazier Life Sciences Management L P$25.46M10.487.38M0%+$01.15
Helm Capital Management LLC$19.2M7.95.56M-2.12%-$415,024.640.57
Viking Global Investors$15.18M6.254.4M0%+$00.01
Vr Adviser Llc$11.81M4.863.42M+<0.01%+$959.100.57
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.